Antifungal drugs are used to treat fungal infections in individuals. Common fungal infections such as fungal nail infection, and ringworm etc. usually occur on the external surface of the body, while certain invasive fungal infections occur inside the body tissues or inside internal organs such as lungs and brain. Fungal infection is usually associated with individuals having weak immune system, such as people suffering from HIV/AIDS. Moreover, patients undergoing chemotherapy are susceptible to invasive fungal infections. Antifungal drugs act against the fungal infections by either killing the fungal cells or by inhibiting their growth. Antifungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.
Market Dynamics
Major players in the market are focused on growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution rights of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for the treatment of life-threatening invasive mold infections in regions like Russia, Israel, Europe (excluding Nordics), and Turkey.
Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive growth of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from their first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for antifungal treatment.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook